$159,76
-$0,98(-0,60 %)
*Data last updated: 2026-05-23 07:26 (UTC+8)
As of 2026-05-23 07:26, Neurocrine Biosciences Inc. (NBIX) is priced at $159,76, with a total market cap of $15,75B, a P/E ratio of 29,48, and a dividend yield of 0,00 %. Today, the stock price fluctuated between $155,00 and $160,90. The current price is 3,07 % above the day's low and 0,70 % below the day's high, with a trading volume of 723,99K. Over the past 52 weeks, NBIX has traded between $152,50 to $160,90, and the current price is -0,70 % away from the 52-week high.
NBIX Key Stats
Yesterday's Close$155,50
Market Cap$15,75B
Volumen723,99K
P/E Ratio29,48
Dividend Yield (TTM)0,00 %
Diluted EPS (TTM)6,65
Net Income (FY)$478,60M
Revenue (FY)$2,86B
Earnings Date2026-07-29
EPS Estimate2,11
Revenue Estimate$866,70M
Shares Outstanding101,32M
Beta (1Y)0.336
About NBIX
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
SectorHealthcare
IndustryBiotechnology
CEOKyle W. Gano
HeadquartersSan Diego,CA,US
Official Websitehttps://www.neurocrine.com
Employees (FY)2,00K
Average Revenue (1Y)$1,43M
Net Income per Employee$239,30K
Neurocrine Biosciences Inc. (NBIX) FAQ
What's the stock price of Neurocrine Biosciences Inc. (NBIX) today?
x
Neurocrine Biosciences Inc. (NBIX) is currently trading at $159,76, with a 24h change of -0,60 %. The 52-week trading range is $152,50–$160,90.
What are the 52-week high and low prices for Neurocrine Biosciences Inc. (NBIX)?
x
What is the price-to-earnings (P/E) ratio of Neurocrine Biosciences Inc. (NBIX)? What does it indicate?
x
What is the market cap of Neurocrine Biosciences Inc. (NBIX)?
x
What is the most recent quarterly earnings per share (EPS) for Neurocrine Biosciences Inc. (NBIX)?
x
Should you buy or sell Neurocrine Biosciences Inc. (NBIX) now?
x
What factors can affect the stock price of Neurocrine Biosciences Inc. (NBIX)?
x
How to buy Neurocrine Biosciences Inc. (NBIX) stock?
x
Risk Warning
The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.
